ONO-7436 [aprepitant] phase II study − A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to examine the efficacy and safety of ONO-7436 for the prevention of cancer chemotherapy-induced nausea and vomiting in Japan.
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2012
At a glance
- Drugs Aprepitant (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 13 Nov 2005 New trial record.